New Sickle Cell drug comes at 1% of global price of ₹77,000

Indian pharmaceutical company Akums Drugs and Pharmaceuticals has launched the country’s first indigenous Hydroxyurea oral solution to treat Sickle Cell Disease. Remarkably, it will cost merely one per cent of the price of global brands of approximately ₹77,000. The Hydroxyurea oral solution reduces the number of painful crises the condition causes and decreases the need for blood transfusions.